SCHEMBL419000

SCHEMBL419000

COC(=O)c1cc(Cl)ccc1NC(=O)CCc1cccc(-c2ccoc2)c1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 5/20 0.60
KDM4E B2RXH2 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
HCAR2 Q8TDS4 3/20 0.46
CNR1 P21554 1/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43
PPARD Q03181 1/20 0.42
NR1H4 Q96RI1 1/20 0.42
HPGD P15428 2/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
RXFP1 Q9HBX9 1/20 0.40
NR4A2 P43354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL418556 0.90 SERPINE1 (0.61) SERPINE1KDM4ESMN1; SMN2CNR1HPGD
SCHEMBL420159 0.89 SERPINE1 (0.71) SERPINE1SMN1; SMN2HCAR2CNR1ALOX15
SCHEMBL1015802 0.84 SERPINE1 (0.84) SERPINE1KDM4ESMN1; SMN2CNR1MAPK1
SCHEMBL1016838 0.84 SERPINE1 (0.81) SERPINE1KDM4ESMN1; SMN2CNR1HPGD
SCHEMBL419148 0.83 SERPINE1 (0.82) SERPINE1KDM4ESMN1; SMN2NPC1ALDH1A1
SCHEMBL417030 0.82 SERPINE1 (0.59) SERPINE1CNR1NPC1
SCHEMBL1015662 0.82 SERPINE1 (0.64) SERPINE1KDM4ESMN1; SMN2CNR1ALOX15
SCHEMBL1012933 0.82 SERPINE1 (0.61) SERPINE1KDM4ESMN1; SMN2CNR1ALOX15
SCHEMBL419057 0.81 SERPINE1 (0.78) SERPINE1SMN1; SMN2CNR1HPGDNPC1
SCHEMBL1015797 0.81 SERPINE1 (0.50) SERPINE1KDM4EALDH1A1GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885KDM4E 4490/4885SMN1; SMN2 2569/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885KDM4E 4490/4885SMN1; SMN2 2569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.